Teradata (NYSE:TDC – Get Free Report) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided EPS guidance of 2.300-2.340 for the period, compared to the consensus EPS estimate of 2.250. The company issued revenue guidance of $1.8 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Teradata also updated its Q4 guidance to $0.40-$0.44 EPS.
Teradata Trading Up 0.5 %
Teradata stock traded up $0.15 during midday trading on Monday, hitting $33.38. 1,207,560 shares of the stock were exchanged, compared to its average volume of 933,884. The company has a fifty day simple moving average of $29.96 and a two-hundred day simple moving average of $31.72. The stock has a market capitalization of $3.21 billion, a PE ratio of 52.97, a P/E/G ratio of 2.99 and a beta of 0.79. Teradata has a 52 week low of $24.02 and a 52 week high of $49.44. The company has a quick ratio of 0.72, a current ratio of 0.75 and a debt-to-equity ratio of 6.87.
Teradata (NYSE:TDC – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The technology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.16. Teradata had a return on equity of 114.57% and a net margin of 3.45%. The company had revenue of $436.00 million during the quarter, compared to the consensus estimate of $447.30 million. During the same period in the prior year, the company earned $0.20 earnings per share. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. Equities research analysts anticipate that Teradata will post 1.3 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Analysis on Teradata
Insider Activity
In other news, insider Hillary Ashton sold 14,962 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $27.53, for a total value of $411,903.86. Following the transaction, the insider now directly owns 121,382 shares of the company’s stock, valued at $3,341,646.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Margaret A. Treese sold 5,500 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $28.50, for a total value of $156,750.00. Following the completion of the sale, the insider now owns 96,783 shares of the company’s stock, valued at approximately $2,758,315.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Hillary Ashton sold 14,962 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $27.53, for a total transaction of $411,903.86. Following the transaction, the insider now directly owns 121,382 shares in the company, valued at approximately $3,341,646.46. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.92% of the company’s stock.
Teradata Company Profile
Teradata Corporation, together with its subsidiaries, provides a connected multi-cloud data platform for enterprise analytics. The company offers Teradata Vantage, an open and connected platform designed to leverage data across an enterprise. Its business consulting services include support services for organizations to establish a data and analytic vision, enable a multi-cloud ecosystem architecture, and identify and operationalize analytical opportunities, as well as to ensure the analytical infrastructure delivers value.
Featured Articles
- Five stocks we like better than Teradata
- Consumer Discretionary Stocks Explained
- Intel: Is Now the Time to Be Brave?
- The 3 Best Blue-Chip Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Does a Stock Split Mean?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Teradata Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teradata and related companies with MarketBeat.com's FREE daily email newsletter.